Open AccessEnhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test
Author(s) -
Sherrif F. Ibrahim,
Julia M. Kasprzak,
Mary Hall,
Alison L. Fitzgerald,
Jennifer J. Siegel,
Sarah J. Kurley,
Kyle R. Covington,
Matthew S. Goldberg,
Aaron S. Farberg,
Shan C. Trotter,
Kenneth L. Reed,
David G. Brodland,
Shlomo A. Koyfman,
AllyKhan Somani,
Sarah T. Arron,
Ashley Wysong
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1277
Subject(s) - medicine , oncology , metastasis , risk assessment , risk factor , population , cancer , pathology , computer security , environmental health , computer science
Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan–Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for class 1 and ≥50% for class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.